Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to $76.7 million.

  • Taysha Gene Therapies' Cash from Financing Activities rose 33.39% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $224.7 million, marking a year-over-year increase of 208.65%. This contributed to the annual value of $76.7 million for FY2024, which is 43.78% down from last year.
  • According to the latest figures from FY2024, Taysha Gene Therapies' Cash from Financing Activities is $76.7 million, which was down 43.78% from $136.4 million recorded in FY2023.
  • Taysha Gene Therapies' Cash from Financing Activities' 5-year high stood at $291.1 million during FY2020, with a 5-year trough of $39.1 million in FY2021.
  • Over the past 3 years, Taysha Gene Therapies' median Cash from Financing Activities value was $76.7 million (recorded in 2024), while the average stood at $88.4 million.
  • In the last 5 years, Taysha Gene Therapies' Cash from Financing Activities tumbled by 86.57% in 2021 and then spiked by 161.81% in 2023.
  • Yearly analysis of 5 years shows Taysha Gene Therapies' Cash from Financing Activities stood at $291.1 million in 2020, then tumbled by 86.57% to $39.1 million in 2021, then soared by 33.30% to $52.1 million in 2022, then soared by 161.81% to $136.4 million in 2023, then tumbled by 43.78% to $76.7 million in 2024.